Monthly Prescribing Reference

Zyprexa Intramuscular

Zyprexa Intramuscular Warnings/Precautions Warnings/Precautions Relprevv: post-injection delirum/sedation syndrome: monitor after each injection. Elderly with dementia-related psychosis (not approved ...
Business Wire

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in ...

PARSIPPANY, N.J. & TEL AVIV & PARIS--(BUSINESS WIRE)--ACCESS HERE THE COMPLETE PRESS RELEASE Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and ...
Business Wire

Medincell’s partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial ...
Monthly Prescribing Reference

Zyprexa Zydis

Olanzapine 5mg, 10mg, 15mg, 20mg; orally-disintegrating tabs; contains phenylalanine. Bipolar disorder: Monotherapy: initially 10–15mg once daily; may increase by 5mg/day. Concomitant lithium or ...
FiercePharma

Uzedy partners Teva and MedinCell's latest long-acting schizophrenia candidate notches phase 3 win

After bringing slow-release schizophrenia drug Uzedy to market last year, Teva and France’s MedinCell are using the same playbook for a similar candidate. With a phase 3 win, the duo is on their way ...